ResMed Inc. (RMD) has consistently beaten estimates in its quarterly earnings for Q1, Q2, and Q3, despite a decrease in margins. The stock, however, has been underperforming in the market, culminating in a fall on a Friday, reflective of the CEO's decision to sell over 14,000 shares. Regardless, the company appears to be in good shape financially and operationally with strong fundamentals, sensible debt usage, and robust growth forecasted for the long-term. Institutional investors, owning 61% of the company, and International Assets Investment Management LLC's acquisition of over 22,000 shares, substantiate the confidence in its performance. Its new product releases, the
AirCurve 11 and the smallest full-face
CPAP Mask AirFit F40, support the claim. Nevertheless, issues of insider selling persist with CFO Brett Sandercock selling 3,000 shares. The company's resilience in face of competition from weight-loss drugs adds to positive sentiments. The valuation suggests a significant undervaluation of
ResMed (RMD) with an inherent margin of safety, implying opportunity for potential investors.
Resmed RMD News Analytics from Fri, 04 Aug 2023 07:00:00 GMT to Sun, 12 May 2024 11:47:32 GMT -
Rating 2
- Innovation 7
- Information 7
- Rumor 5
